Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024
This study is recruiting at 8 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Renal Cell Carcinoma
- Urothelial Carcinoma
- Castration-resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Deciphera Pharmaceuticals, LLC
- Last updated on ClinicalTrials.gov
- August 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Michigan · 1
- University of Michigan · Ann Arbor, MI
Missouri · 1
- Washington University School of Medicine · St Louis, MO
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Pennsylvania · 1
- Fox Chase Cancer Center · Philadelphia, PA
Tennessee · 1
- Vanderbilt- Ingram Cancer Center · Nashville, TN
Texas · 2
- NEXT Oncology, Austin · Austin, TX
- NEXT Oncology, San Antonio · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.